MX2013005016A - Composiciones y métodos para la entrega de ácido nucleico a base de nanopolímeros. - Google Patents
Composiciones y métodos para la entrega de ácido nucleico a base de nanopolímeros.Info
- Publication number
- MX2013005016A MX2013005016A MX2013005016A MX2013005016A MX2013005016A MX 2013005016 A MX2013005016 A MX 2013005016A MX 2013005016 A MX2013005016 A MX 2013005016A MX 2013005016 A MX2013005016 A MX 2013005016A MX 2013005016 A MX2013005016 A MX 2013005016A
- Authority
- MX
- Mexico
- Prior art keywords
- nucleic acid
- methods
- compositions
- nanopolymer
- acid delivery
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
En la presente se proporcionan las composiciones nanopartícula/ácido nucleico p-GlcNAc. En un aspecto, las composiciones de nanopartícula/ácido nucleico p-GlcNAc contienen nanopartículas de derivado polilactato de N-acetilgiucosamina desacetilado de menos de 500 nm y un ácido nucleico. Asimismo, en la presente se proporcionan los métodos para administrar un ácido nucleico a un individuo, el método consiste en administrar al individuo una composición nanopartícula/ácido nucleico p-GlcNAc. En ciertas modalidades, la composición de nanopartícula/ácido nucleico p-GlcNAc se administra por vía subcutánea al individuo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41086310P | 2010-11-06 | 2010-11-06 | |
| US41135810P | 2010-11-08 | 2010-11-08 | |
| PCT/US2011/059558 WO2012061803A2 (en) | 2010-11-06 | 2011-11-07 | Compositions and methods for nanopolymer-based nucleic acid delivery |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013005016A true MX2013005016A (es) | 2014-03-12 |
| MX358050B MX358050B (es) | 2018-08-03 |
Family
ID=46025153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013005016A MX358050B (es) | 2010-11-06 | 2011-11-07 | Composiciones y métodos para la entrega de ácido nucleico a base de nanopolímeros. |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20130287853A1 (es) |
| EP (1) | EP2635261B1 (es) |
| JP (2) | JP6029591B2 (es) |
| CN (2) | CN103282024A (es) |
| AU (3) | AU2013203247A1 (es) |
| CA (1) | CA2816999A1 (es) |
| ES (1) | ES2763432T3 (es) |
| IL (1) | IL226170B (es) |
| MX (1) | MX358050B (es) |
| WO (1) | WO2012061803A2 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3000487B8 (en) | 2007-02-19 | 2022-06-15 | Marine Polymer Technologies, Inc. | Hemostatic compositions and therapeutic regimens |
| NZ703163A (en) | 2010-04-15 | 2016-06-24 | Marinepolymer Tech Inc | Anti-bacterial applications of poly-n-acetylglucosamine nanofibers |
| WO2012061803A2 (en) * | 2010-11-06 | 2012-05-10 | Marine Polymer Technologies, Inc. | Compositions and methods for nanopolymer-based nucleic acid delivery |
| CN107362171A (zh) | 2011-04-15 | 2017-11-21 | 海洋聚合物技术公司 | 用聚‑n‑乙酰基葡糖胺纳米纤维治疗疾病 |
| CA2968160C (en) * | 2016-05-31 | 2024-01-02 | Sachiko Sato | Use of n-acetylglucosamine and derivatives thereof to treat muscle disorders |
| EP3693024A1 (en) * | 2019-02-05 | 2020-08-12 | Altona Diagnostics GmbH | Control for nucleic acid preparation and/or detection methods |
| IT202200004574A1 (it) * | 2022-03-10 | 2023-09-10 | Sergio Ammendola | Nanoparticelle di N-acetilglucosammina e loro applicazioni |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| GB0126923D0 (en) * | 2001-11-09 | 2002-01-02 | Procter & Gamble | Chitosan compositions |
| US7780873B2 (en) * | 2004-02-23 | 2010-08-24 | Texas A&M University System | Bioactive complexes compositions and methods of use thereof |
| JP2005281239A (ja) * | 2004-03-30 | 2005-10-13 | Nippon Zeon Co Ltd | 鶏用ｄｎａワクチン |
| US20060105049A1 (en) * | 2004-11-12 | 2006-05-18 | Valorisation Recherche Hscm & Universite De Montreal | Folic acid-chitosan-DNA nanoparticles |
| EP2357184B1 (en) | 2006-03-23 | 2015-02-25 | Novartis AG | Imidazoquinoxaline compounds as immunomodulators |
| EP2007765B1 (en) | 2006-03-23 | 2012-06-27 | Novartis AG | Immunopotentiating compounds |
| EP2068917A2 (en) * | 2006-09-22 | 2009-06-17 | Government of the USA, as Represented by the Secretary, Department of Health and Human Services | Compositions and methods for chitosan enhanced immune response |
| KR100882611B1 (ko) * | 2006-11-14 | 2009-02-12 | 주식회사 키토라이프 | 표적 리간드로서 폴릭산이 도입된 유전자 전달체용저분자량 수용성 키토산 나노입자 및 이의 제조방법 |
| US8252771B2 (en) * | 2007-01-31 | 2012-08-28 | Allergan, Inc. | Biomaterials and a method for making and using same |
| US20100086613A1 (en) * | 2008-10-03 | 2010-04-08 | Chang-Jer Wu | Chitosan vehicle and method for making same |
| US20100105139A1 (en) * | 2008-10-27 | 2010-04-29 | Remco Alexander Spanjaard | Ligand Targeted Nanocapsules for the delivery of RNAi and other Agents |
| CA2833415A1 (en) * | 2010-05-10 | 2011-11-17 | Corporation De L'ecole Polytechnique De Montreal | Gene therapy for diabetes with chitosan-delivered plasmid encoding glucagon-like peptide 1 |
| WO2012061803A2 (en) * | 2010-11-06 | 2012-05-10 | Marine Polymer Technologies, Inc. | Compositions and methods for nanopolymer-based nucleic acid delivery |
-
2011
- 2011-11-07 WO PCT/US2011/059558 patent/WO2012061803A2/en active Application Filing
- 2011-11-07 CN CN2011800636609A patent/CN103282024A/zh active Pending
- 2011-11-07 ES ES11838933T patent/ES2763432T3/es active Active
- 2011-11-07 US US13/883,527 patent/US20130287853A1/en not_active Abandoned
- 2011-11-07 MX MX2013005016A patent/MX358050B/es active IP Right Grant
- 2011-11-07 CN CN201810672707.5A patent/CN108743562A/zh active Pending
- 2011-11-07 AU AU2013203247A patent/AU2013203247A1/en not_active Abandoned
- 2011-11-07 CA CA2816999A patent/CA2816999A1/en not_active Abandoned
- 2011-11-07 EP EP11838933.7A patent/EP2635261B1/en active Active
- 2011-11-07 AU AU2011323078A patent/AU2011323078B2/en active Active
- 2011-11-07 JP JP2013537902A patent/JP6029591B2/ja active Active
-
2013
- 2013-05-05 IL IL226170A patent/IL226170B/en active IP Right Grant
-
2016
- 2016-03-15 AU AU2016201640A patent/AU2016201640A1/en not_active Abandoned
- 2016-04-13 JP JP2016080377A patent/JP2016164181A/ja active Pending
- 2016-06-24 US US15/192,356 patent/US20170128382A1/en not_active Abandoned
-
2022
- 2022-07-01 US US17/856,655 patent/US20230157971A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012061803A2 (en) | 2012-05-10 |
| AU2011323078B2 (en) | 2016-04-14 |
| EP2635261B1 (en) | 2019-10-23 |
| AU2011323078A1 (en) | 2013-05-02 |
| WO2012061803A3 (en) | 2012-08-16 |
| EP2635261A4 (en) | 2014-09-17 |
| CA2816999A1 (en) | 2012-05-10 |
| EP2635261A2 (en) | 2013-09-11 |
| CN103282024A (zh) | 2013-09-04 |
| US20170128382A1 (en) | 2017-05-11 |
| JP2016164181A (ja) | 2016-09-08 |
| AU2013203247A1 (en) | 2013-05-09 |
| JP6029591B2 (ja) | 2016-11-24 |
| US20230157971A1 (en) | 2023-05-25 |
| US20130287853A1 (en) | 2013-10-31 |
| IL226170A0 (en) | 2013-07-31 |
| MX358050B (es) | 2018-08-03 |
| ES2763432T3 (es) | 2020-05-28 |
| CN108743562A (zh) | 2018-11-06 |
| JP2014500250A (ja) | 2014-01-09 |
| AU2016201640A1 (en) | 2016-04-07 |
| IL226170B (en) | 2018-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX358050B (es) | Composiciones y métodos para la entrega de ácido nucleico a base de nanopolímeros. | |
| MX342439B (es) | Metodos para producir nanoparticulas polimericas y formulaciones de ingredientes activos. | |
| NZ604063A (en) | Compositions and methods for enhancing physiological performance and recovery time | |
| MY173008A (en) | Methods and compositions for improving gut microbiota population | |
| IN2014KN00996A (es) | ||
| MX2020007227A (es) | Nanoparticulas farmaceuticas que muestran la mejora del transporte de la mucosa. | |
| PH12015500407B1 (en) | Methods of treating hypertriglyceridemia | |
| WO2014004861A3 (en) | Methods of treating pediatric metabolic syndrome | |
| WO2010087964A3 (en) | Compositions for treatment and prevention of acne, methods of making the compositions, and methods of use thereof | |
| WO2013041975A3 (en) | Pyrethroid formulations | |
| IL227623B (en) | Preparations of extremely tiny particles containing a population of particles, for use in creating a medicine for topical treatment in patients who suffer or tend to suffer from a disease related to the sweat glands and/or the mammary glands | |
| WO2012101639A3 (en) | Nanoparticles based for dermal and systemic delivery of drugs | |
| WO2011099832A3 (en) | Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same | |
| NZ595987A (en) | A novel formulation of diclofenac | |
| WO2012104275A3 (en) | Nanoparticles delivery systems, preparation and uses thereof | |
| WO2012047733A3 (en) | Treatment of acne by conditioned media | |
| WO2011069010A3 (en) | Amantadine compositions and methods of use | |
| WO2012107865A3 (en) | Modulation of growth of bifidobacteria using a combination of oligosaccharides found in human milk | |
| TN2012000574A1 (en) | Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactate monohydrate | |
| WO2013087734A3 (en) | Functionalised silicon nanoparticles | |
| BR112014014832A2 (pt) | formulação e método de controlar fungos | |
| WO2012121528A3 (en) | Magnetic nanocomposite specific for thyroid cancer and use thereof | |
| WO2013156488A3 (en) | Optimised subcutaneous therapeutic agents | |
| MY165003A (en) | Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative | |
| NZ722319A (en) | A novel formulation of meloxicam |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |